Insider · SEC Form 4 filer

David Wambeke

Companies

Where they file as an insider

Neuroone Medical Technologies (NMTC) Chief Business Officer Latest filing Aug 27, 2026
DiaMedica Therapeutics (DMAC) Chief Business Officer Latest filing Nov 16, 2023

Track record

Did their buys beat the typical stock?

Open-market buys3
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check1

Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.

Neuroone Medical Technologies (NMTC) Bought Aug 27, 2026 · $67K · 33,333 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Neuroone Medical Technologies (NMTC) Bought Mar 1, 2026 · $670K · 1M shares Beat typical Mar 31, 2026 $0.78 → Sep 30, 2026 $1.03 · +32.6% (typical stock +1.7%)
DiaMedica Therapeutics (DMAC) Bought Nov 16, 2023 · $49.2K · 20,000 shares Beat typical Dec 31, 2023 $2.84 → Jun 30, 2024 $2.95 · +3.9% (typical stock −1.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist